Intravitreal injection with Ranibizumab combined with laser therapy for macular edema caused by branch retinal vein occlusion
10.3980/j.issn.1672-5123.2014.08.08
- VernacularTitle:玻璃体腔注射Ranibizumab联合激光治疗 BRVO继发黄斑水肿的观察
- Author:
Zhang, CONG
;
Xu, HE
;
Xu, LI
- Publication Type:Journal Article
- Keywords:
ranibizumab;
branch retinal vein occlusion;
macular edema
- From:
International Eye Science
2014;(8):1399-1402
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To investigate the efficacy of intravitreal ranibizumab combined with laser therapy in the treatment of macular edema caused by branch retinal vein occlusion ( BRVO) .
METHODS:There were 78 patients (78 eyes) who were diagnosed with macular edema caused by BRVO using fundus fluorescence angiography ( FFA ) and optical coherence tomography ( OCT ) . Group A: randomly selected 26 cases ( 26 eyes ) were given grid laser photocoagulation ( GLP) . Group B: randomly selected 26 cases (26 eyes) were given GLP first, and then received intravitreal ranibizumab 1wk later. Group C: randomly selected 26 cases ( 26 eyes ) undergone intravitreal ranibizumab first, and then given GLP 1wk later. There was no significant difference in macular edema. We analyzed the changes in the best corrected visual activity ( BCVA ) , central macular thickness ( CMT ) before and 1wk, 1,6mo after treatment.
RESULTS: Compared with before treatment, 1wk after treatment: mean value changes of BCVA and CMT were no significant difference in group A (P>0. 05);mean value changes of BCVA was improved and mean value of CMT was decreased in groups B and C, the difference was statistically significant (P<0. 05);BCVA and CMT changes between groups had statistical significance ( P<0. 01 );After treatment 1, 6mo:compared with before treatment, mean BCVA was improved in three groups, mean CMT was lower, the differences were statistically significant (P<0. 01);BCVA and CMT changes between groups were statistically significant ( P<0. 05 ); compared with 1mo after treatment, mean BCVA and CMT were no significant difference (P>0.05) between groups A and B after 6mo treatment;mean BCVA improved and CMT average value was decreased in group C, the difference was statistically significant ( P<0.01 ); BCVA and CMT changes between groups were statistically significant (P<0. 01).
CONCLUSION: Intravitreal injection ranibizumab combined laser therapy can effectively reduce BRVO induced macular edema, enhance vision acuity. Compared with GLP, combination therapy has more rapid onset of treatment, and reduce macular edema better; Intravitreal ranibizumab should be given in front of the GLP, and the treatment effect is more precise, more stability.
